VEL Vaccines Biosciences is a pre-clinical stage biopharmaceutical company developing vaccines for transformation of management of cancer and infectious disease. VEL (Variable Epitope Library) vaccine technology was developed to address the need for effective immunization strategies against antigenically variable targets. The main limitation of current technologies is their inability to elicit sustained, protective immune responses against these constantly changing targets. VEL vaccines anticipate large numbers of mutational outcomes in the target and challenge host immune defenses with thousands and tens of thousands of epitopes. Immune systems primed with VEL-vaccines produce unprecedented repertoires of T-cells capable of containing and neutralizing disease caused by antigenically variable targets.